Frequently Asked Questions
Can foreigners join clinical trials in China?
There is no nationality restriction in China's clinical trial regulations — eligibility is defined by each trial's inclusion and exclusion criteria. In practice, treatment trials (for example oncology trials) are realistic for foreigners who can travel to China and attend the trial site, while the paid "healthy volunteer" Phase 1 circuit is mostly closed to foreigners because screening normally requires a Chinese ID card.
Do I have to pay to join a clinical trial in China?
No. Under Chinese GCP rules the sponsor must provide the investigational drug free of charge and pay for trial-related medical tests, plus treatment and compensation if you are harmed by the trial. You pay for travel, accommodation, and any non-trial medical care. Anyone charging you a "registration" or "enrollment" fee is a red flag.
Can I apply to a Chinese clinical trial from abroad?
Yes — initial contact and medical records review can be done remotely, and documented international cases started exactly this way. Screening, treatment, and monitoring require you to be in China; for CAR-T therapy plan roughly 6–8 weeks on the ground.
What visa do I need to get treatment in China?
China has no dedicated national "medical visa". The standard routes are an L (tourist) visa or an S1/S2 (private affairs) visa supported by a hospital invitation letter. Hainan province is the exception: citizens of 59 countries can enter visa-free for up to 30 days with medical treatment as an explicit purpose, and Boao Lecheng patients can obtain a stay matching their treatment duration.
Is language a problem for joining a trial in China?
China's main registry (the CDE platform) is Chinese-only, so use your browser's translation feature or start with ClinicalTrials.gov. Your informed consent must be provided in language you understand — that is a GCP requirement — and hospitals with international patient departments (for example in Shanghai and Beijing) provide translation support.
What is the difference between joining a trial and paying for CAR-T in China?
A clinical trial provides the investigational therapy free of charge but has strict medical criteria and a fixed protocol schedule. Commercial treatment means paying for an approved therapy — nine CAR-T products were approved in China as of September 2026, with reported prices around US$150,000–230,000. Both routes have brought foreign patients to Chinese hospitals since 2025.
Quick Summary: China now runs one of the world’s largest clinical trial systems — more than 55,000 studies on the international registry have locations in China and over 11,000 are currently recruiting. Chinese rules contain no nationality bar, and a wave of 2026 press coverage (Bloomberg, WSJ) documented foreign patients flying in for CAR-T cancer therapy at a fraction of US prices — some through trials, some by paying for approved treatments. This guide shows you how to find trials in China’s three official registries, how to contact a trial site, what your rights are under Chinese GCP, and the red flags to avoid.
This guide is information only. We are not a hospital and we do not arrange, recommend, or broker trial enrollment. You should always contact trial sites directly and make medical decisions with your own doctors.
Why Foreigners Are Looking at China for Clinical Trials
Three things changed at once in 2025–2026.
The science moved. China now has the world’s largest CAR-T clinical trial activity and, as of September 2026, nine approved CAR-T therapies — more than any other country (WSJ, Sept 6, 2026). CAR-T (chimeric antigen receptor T-cell) therapy reprograms your own immune cells to attack cancer, and has produced strong results in blood cancers such as lymphoma, leukemia, and myeloma.
The price gap became public. In the US, a single CAR-T infusion costs US$300,000–475,000 (American Cancer Society figures cited by Bloomberg). Reporting in 2026 put the equivalent treatment in China at roughly US$150,000–230,000 (WSJ, Asia Times, Sept 8, 2026) — and an application is pending for a CAR-T priced below ¥300,000 (~US$42,000) (Bloomberg via Straits Times, June 11, 2026). For comparison, China’s first approved CAR-T launched at ¥1.2 million in 2021, so prices are moving down fast.
Real patients documented the path. Bloomberg profiled Stuart Lye, a 58-year-old New Zealander with myeloma, who was quoted over A$500,000 in Australia — and paid about US$65,000 all-in, including flights, for seven weeks in a clinical trial in Shanghai that brought his cancer under control. The Wall Street Journal followed Michael Walters, 24, from Auckland, who was declared in complete remission in August 2026 after CAR-T in Shanghai, and an Australian patient who paid “less than half” the US$600,000 quoted at home (Asia Times). Shanghai providers now publish international patient journeys: SinoUnited Health has treated about 30 foreign CAR-T patients since late 2024, and Jiahui International Cancer Center has documented a Pakistani patient’s full CAR-T journey, including translation and halal catering (PR Newswire, May 25, 2026).
On the numbers: 55,288 studies on ClinicalTrials.gov have locations in China, and 11,754 are currently recruiting (our count via the ClinicalTrials.gov API, October 12, 2026). And that undercounts domestic activity — see the registry section below.
Trial vs. Approved Treatment: Two Different Doors
Foreign patients reach advanced treatment in China through two different doors, and it matters which one you are looking at:
| Clinical trial | Approved (commercial) treatment | |
|---|---|---|
| What it is | An investigational therapy being tested under a regulated protocol | A therapy already approved by China’s NMPA |
| What you pay | The drug and trial-related tests are free — the sponsor pays | You pay; CAR-T reported at US$150,000–230,000 in 2026 |
| Who qualifies | Strict inclusion/exclusion criteria (cancer type, stage, prior treatments, organ function…) | Criteria set by the treating hospital; generally broader |
| Schedule | Fixed protocol visits, possible control arms, longer commitment | Scheduled by you and your doctor |
| Best for | Patients who match a trial’s criteria and want access to therapies not yet approved anywhere | Patients who want a specific approved therapy now |
Stuart Lye joined a trial. Michael Walters reportedly received commercial treatment funded by a New Zealand fundraiser (about NZ$500,000 had been quoted overseas; 1News). Both routes are real — the rest of this guide is about the trial route, with the cost context you need for both.
Can Foreigners Actually Join a Clinical Trial in China?
The short answer: nothing in Chinese regulation stops you, but each trial’s medical criteria decide everything.
- China’s Good Clinical Practice (GCP) rules — the regulations governing drug trials — contain no nationality or citizenship restriction. A “trial subject” is simply a person who receives an investigational drug, whether patient or healthy volunteer, and eligibility is defined by each protocol’s inclusion and exclusion criteria, which an ethics committee must review before the trial starts.
- For treatment trials (for example, oncology trials), what matters in practice is: your diagnosis matches the protocol, you can travel to China and attend the trial site for every visit, and the site team accepts your passport as identification. Globally-run trials with Chinese sites routinely enroll patients of any nationality — see for example NCT06790693, a Phase 3 breast cancer trial recruiting at 23 Chinese sites with no nationality or ethnicity requirement.
- Ethics-based restrictions do exist in some trials. A meaningful share of Chinese trials — especially Phase 1 and bioequivalence studies — require participants of Chinese ethnicity (171 trials with China locations on ClinicalTrials.gov mention “Han Chinese” in their criteria). Read the eligibility section carefully.
- The paid “healthy volunteer” circuit is mostly closed to foreigners. Phase 1 trials testing drugs in healthy people pay volunteers, and screening in China normally requires a Chinese ID card for real-name verification against a national volunteer database that prevents double enrollment. Some sites accept passports, but there is no established pathway for foreign healthy volunteers — do not travel to China expecting to join paid Phase 1 trials.
One more practical point: your home doctor’s support matters. You will need complete medical records to pre-screen, and a specialist who can discuss the trial protocol with you is invaluable.
The Three Official Registries: How to Search
Every legitimate drug trial in China is registered on an official registry. If a “trial” you are offered cannot be found on one of these three, walk away.
1. ClinicalTrials.gov — start here if you read English
The US National Library of Medicine registry, in English. Most international trials run in China (and many China-led ones) are listed with full eligibility criteria in English.
- Go to clinicaltrials.gov and type your condition into the search box
- On the results page, open the sidebar filters and set Study status → Recruiting and Location → China — or use this direct link for recruiting studies in China
- Open each study and read the Eligibility section (inclusion and exclusion criteria), the Locations tab (which hospitals), and the Contacts section
Registration on ClinicalTrials.gov is not mandatory for trials that run only inside China, so also check the two registries below.
2. The CDE platform — China’s mandatory national registry
The Drug Clinical Trial Registration and Information Platform (药物临床试验登记与信息公示平台), run by the Center for Drug Evaluation of the National Medical Products Administration, is where every drug trial approved to run in China must be registered and publicly disclosed — including domestic trials you will not find anywhere else. The interface is Chinese-only; use your browser’s translate function.
How to search:
- Open chinadrugtrials.org.cn — the homepage search box and the 高级查询 (Advanced Query) button both work without an account
- Enter a search term. The advanced query fields are:
| Chinese field | English | What to enter |
|---|---|---|
| 适应症 | Indication | Your disease in Chinese, e.g. 淋巴瘤 (lymphoma), 多发性骨髓瘤 (multiple myeloma), 肺癌 (lung cancer) |
| 药物名称 | Drug name | A drug’s Chinese or generic name |
| 申请人 | Sponsor | The company running the trial |
| 主要研究者 | Lead investigator (PI) | The professor heading the trial |
| 临床参加机构 | Participating institutions | A hospital name, e.g. 瑞金医院 |
| 试验状态 | Trial status | Filter to actively recruiting trials |
- Click a result’s registration number to open its public detail page, which shows the sponsor, lead investigator, and contact information for the participating institutions — this is the official channel to reach a trial team
- Registration numbers start with “CTR” — quote this number in any correspondence
3. ChiCTR — the WHO-recognized academic registry
The Chinese Clinical Trial Registry (ChiCTR), run from West China Hospital of Sichuan University, is a WHO Primary Registry with over 131,000 registered trials. It has an English interface: go to chictr.org.cn, switch to English in the top bar, and use Trial Search. It covers investigator-initiated and academic studies that may not appear on the other two registries.
From Search to Enrollment: Step by Step
Based on the journeys documented in press and hospital releases, here is the realistic path:
- Define your case in writing. Diagnosis (with pathology reports), stage, treatments already tried, current status. Get it translated into Chinese — hospitals with international departments can help, or use a medical translation service.
- Search the registries above for your condition + China + recruiting. Build a shortlist of 3–5 trials whose eligibility criteria you appear to meet. Ask your home oncologist to sanity-check each one.
- Contact the trial site directly using the contact information published on the registry (CDE detail pages list participating institutions’ phone contacts; ClinicalTrials.gov lists study contacts). Hospitals with formal international patient departments are the most accessible entry points — for example Beijing GoBroad runs a documented multilingual international patient service ([email protected], patient guide), and Shanghai’s Jiahui and SinoUnited have published international CAR-T programs. Never go through an intermediary who promises “priority enrollment”.
- Remote pre-screening. Send your records; the trial team does an initial eligibility review. In the documented cases this stage took days, not weeks — Bloomberg reported the Lye case moved from first contact to flights in about ten days.
- Sort your visa. China has no dedicated national “medical visa”. The standard routes: an L (tourist) visa, or an S1/S2 (private affairs) visa supported by a hospital invitation letter (PRC visa categories). Hainan is the exception: citizens of 59 countries can enter visa-free for up to 30 days with medical treatment as an explicit purpose, and Boao Lecheng international patients can obtain a stay matching their treatment duration (NIA measures). See our guide to Chinese visa types and extensions.
- Travel and on-site screening. Expect blood tests, imaging, and physical checks to confirm you meet every criterion. Screening can disqualify you at this stage — that is the system working, not a scam.
- Informed consent, then treatment. If you pass screening, you go through the informed consent process (see your rights below) before any trial procedure. For CAR-T, the realistic on-the-ground timeline is 6–8 weeks: cell collection, roughly three weeks of manufacturing, conditioning chemotherapy, infusion, then 1–3 weeks of inpatient monitoring for side effects, plus follow-up visits. The documented international cases fit this window.
Your Rights as a Trial Participant in China
China’s GCP rules have required the following protections for years — they are long-standing requirements of the 2020 GCP and are carried forward in the 2026 revision (Announcement No. 50 of 2026, effective September 1, 2026), which restructures the rules in line with ICH E6(R3):
- Informed consent in language you understand. Consent must follow the Declaration of Helsinki’s ethical principles, use plain language, and be documented with your dated signature. You may not be pressured or induced into joining.
- Voluntary participation, withdrawal anytime. You can refuse to join, or leave the trial at any stage, without discrimination or any effect on your regular medical care.
- The sponsor pays for the trial. Trial drugs are provided free, the sponsor pays trial-related medical tests, and covers treatment costs plus compensation for injuries or death related to the trial.
- Privacy. Your identity and personal information stay confidential, including in published results.
- Ethics committee oversight. Every trial must be reviewed and approved by an ethics committee whose job is protecting participants’ rights and safety.
An excellent English-language reference is the NIH’s Clinical Regulations database for China, which tracks Chinese trial regulation including the 2026 GCP revision.
What a Clinical Trial in China Costs You
| Item | Who pays |
|---|---|
| Investigational drug | Sponsor (free to you) |
| Trial-related tests and scans | Sponsor |
| Treatment for trial-related injury | Sponsor |
| Flights, visas, accommodation for you (+ companion) | You |
| Non-trial medical care (e.g. treatment for an unrelated condition) | You / your insurance |
| Follow-up visits required by the protocol | Sponsor (within the protocol) |
For commercial CAR-T (not a trial), budget against the reported US$150,000–230,000 range for treatment, plus roughly US$2,000–5,000 for a 6–8 week stay’s flights, accommodation, and living costs. Get an itemized written quote from the hospital before traveling — which therapies and services are included, what triggers extra charges, and what records you will receive. Press reporting in 2026 flagged patients returning home without usable medical records or a plan for paying complications — avoid that by agreeing everything in writing up front (Asia Times).
Payment logistics for hospital deposits and bills (WeChat Pay, cards, wire transfer) are covered in our How to Pay in China guide.
Red Flags: How Clinical Trial Scams Work
The registries above exist partly because unregulated “trials” also exist. Walk away from:
- Anyone charging you to join. “Registration fees”, “matching fees”, “priority enrollment” — legitimate trials are free to join and the sponsor pays trial costs. A fee up front is disqualifying.
- Trials you cannot find on an official registry. Every legitimate drug trial in China has a CTR number on the CDE platform; international trials usually also have an NCT number on ClinicalTrials.gov. No number, no trial.
- Unapproved “cell therapy” or “stem cell” packages sold as treatment. These sit outside the trial and approval system. Bloomberg’s reporting includes the cautionary case of a student who died in 2016 after paying more than ¥200,000 for an unapproved cell therapy.
- Prices that do not match reality. Third-party sites quote CAR-T “packages” anywhere from US$55,000 to US$250,000 with no consistency. Deal directly with the hospital and demand an itemized quote; be skeptical of intermediaries whose numbers shift.
- Claims of a national “medical visa”. It does not exist — only Hainan has medical-specific entry rules. Sites promising special medical visas for mainline China ports are misinformed or worse.
After the Trial: Records and Follow-up
- Before leaving China, request your complete medical records — test results, imaging, treatment summary — in English if possible, plus your treating doctor’s contact information. Our medical trip planning guide has a full pre-departure checklist.
- Arrange home follow-up before you travel. CAR-T patients need long-term monitoring — the US FDA recommends lifelong follow-up for some CAR-T products, and the CDC advises patients to arrange follow-up care and financing before traveling abroad for treatment.
- Share everything with your home specialist immediately, and schedule follow-up appointments before the effect of treatment (or trial protocols) makes travel harder.
Related Guides
- Medical Trip to China: Complete Planning Guide — Hospitals, visas, budgeting
- Healthcare Costs for Foreigners in China — What treatment actually costs
- Medical Tourism in China: Dental, Cosmetic & Health Checks — The lower-cost end of medical travel
- Expat Medical Insurance in China — Coverage options
- How to Pay in China — Payment setup for hospital visits
Medical Disclaimer
This content is for general health education only and does not constitute medical advice, diagnosis, or treatment. We do not provide medical services, do not arrange or broker clinical trial enrollment, and do not endorse specific hospitals, trials, or outcomes. Trial eligibility is determined solely by trial investigators. Treatment decisions should be made in consultation with qualified healthcare professionals.
Sources
Verified against the sources below on 12 October 2026 (UTC).
- NMPA, NHC, National Administration of TCM, National Disease Control Administration — Good Clinical Practice 2026 revision, Announcement No. 50 of 2026 (effective 1 September 2026; repeals the 2020 GCP): nmpa.gov.cn
- NMPA + NHC — Good Clinical Practice 2020 (Announcement No. 57), full text with the participant-rights provisions cited above: gov.cn
- NIH NIAID — Clinical Regulations: China (English-language tracker of Chinese trial regulation, incl. the 2026 GCP): clinregs.niaid.nih.gov
- CDE, NMPA — Drug Clinical Trial Registration and Information Platform (China’s mandatory trial registry): chinadrugtrials.org.cn
- Chinese Clinical Trial Registry (ChiCTR) — WHO ICTRP Primary Registry: chictr.org.cn and the WHO primary registries list
- ClinicalTrials.gov — recruiting studies with locations in China (count basis: 55,288 China-location studies / 11,754 recruiting via the ClinicalTrials.gov API v2, 12 October 2026)
- WSJ — “Patients Are Flying to China for the Latest Cancer Treatment” (Sept 6, 2026; nine approved CAR-Ts; US price ranges): wsj.com
- Bloomberg (Karoline Kan) — “China Lures Foreign Patients With Cutting-Edge, Cheap Medical Care” (June 11, 2026 syndication; Stuart Lye case; SinoUnited figures; CAR-T price data): straitstimes.com
- Asia Times — “Cheaper CAR-T therapy drawing global cancer patients to China” (Sept 8, 2026; timelines, itemized-quote guidance, FDA/CDC follow-up advice): asiatimes.com
- Jiahui International Cancer Center — international CAR-T patient journey (Pakistani patient, April–May 2026): prnewswire.com
- National Immigration Administration — Hainan measures incl. visa-free medical treatment for 59 countries and treatment-duration stays at Boao Lecheng: nia.gov.cn
- PRC Consulate General New York — Chinese visa categories (L; S1/S2 private affairs): newyork.china-consulate.gov.cn
Your trusted guide for life in China.
© 2026 China Neighbor ·Original article: · Last verified:Oct 12, 2026
Reproduction requires attribution with a link to the original.